ARID1A and neoplasm: provided a novel combination therapy of TP06 (epigenetic inhibitor) and Nutlin‐3 (p53 agonist) to treat gastric tumoroids with Arid1a heterozygosity, exhibiting a robust inhibition of tumor growth.